Novartis letrozole
For the adjuvant therapy of postmenopausal women with early breast cancer and a hormone receptor positive, letrozole from Novartis is suggested. Femara is approved for the extended adjuvant treatment of early breast cancer in postmenopausal women who have undergone adjuvant tamoxifen therapy for five years.
₦2,750.00 ₦2,500.00
Reviews
There are no reviews yet.